AR028357A1 - 4-bencil-1-[2-(4-hidroxi-fenoxi)-etil]-piperidin-3,4-diol - Google Patents

4-bencil-1-[2-(4-hidroxi-fenoxi)-etil]-piperidin-3,4-diol

Info

Publication number
AR028357A1
AR028357A1 ARP010101869A ARP010101869A AR028357A1 AR 028357 A1 AR028357 A1 AR 028357A1 AR P010101869 A ARP010101869 A AR P010101869A AR P010101869 A ARP010101869 A AR P010101869A AR 028357 A1 AR028357 A1 AR 028357A1
Authority
AR
Argentina
Prior art keywords
fenoxi
bencil
hidroxi
etil
piperidin
Prior art date
Application number
ARP010101869A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR028357A1 publication Critical patent/AR028357A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C07D211/50—Aroyl radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP010101869A 2000-04-25 2001-04-23 4-bencil-1-[2-(4-hidroxi-fenoxi)-etil]-piperidin-3,4-diol AR028357A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00108769 2000-04-25

Publications (1)

Publication Number Publication Date
AR028357A1 true AR028357A1 (es) 2003-05-07

Family

ID=8168543

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101869A AR028357A1 (es) 2000-04-25 2001-04-23 4-bencil-1-[2-(4-hidroxi-fenoxi)-etil]-piperidin-3,4-diol

Country Status (18)

Country Link
US (1) US6432985B2 (es)
EP (1) EP1278730B1 (es)
JP (1) JP3831255B2 (es)
KR (1) KR100527527B1 (es)
CN (1) CN1178914C (es)
AR (1) AR028357A1 (es)
AT (1) ATE313527T1 (es)
AU (1) AU785153B2 (es)
BR (1) BR0110233A (es)
CA (1) CA2407345C (es)
DE (1) DE60116080T2 (es)
DK (1) DK1278730T3 (es)
ES (1) ES2254422T3 (es)
MX (1) MXPA02010573A (es)
PE (1) PE20011229A1 (es)
UY (1) UY26681A1 (es)
WO (1) WO2001081309A2 (es)
ZA (1) ZA200208134B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7684859B2 (en) 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
WO2004043218A2 (en) 2002-11-14 2004-05-27 Brainsgate Ltd. Surgical tools and techniques for stimulation
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
WO2007076875A2 (en) * 2006-01-06 2007-07-12 Aarhus Universitet Compounds acting on the serotonin transporter
MX2009012506A (es) * 2007-05-21 2009-12-09 Reviva Pharmaceuticals Inc Composiciones, sintesis, y metodos para utilizar agentes antipsicoticos atipicos basados en quinolinona.
US8008253B2 (en) * 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
KR20100135847A (ko) * 2008-03-27 2010-12-27 에보텍 뉴로사이언시즈 게엠베하 Ｎｍｄａ ｎｒ２ｂ―서브타입 선택적 길항제를 사용한 질병 치료 방법
BRPI0917948A2 (pt) * 2008-08-12 2017-06-20 Zinfandel Pharrmaceuticals Inc métodos de identificar uma variante genética que está associada com o desenvolvimento de uma condição de interesse e um paciente em um ensaio clínico de um tratamento para doença de alzheimer, de determinar riscos incrementando de desenvolvimento de uma condição de interesse, doença de alzheimer em um paciente, de um prognóstico ou o risco de desenvolver doença de alzheimer em um paciente, de tratar um paciente para doença de alzheimer, uma condição de interesse e doença de alzheimer em um paciente, de estratificar um paciente em um subgrupo de um ensaio clínico de uma terapia para o tratamento de doença de alzheimer, uso de um agente ativo anti-doença de alzheimer e kits para determinar se um paciente encontra-se em risco incrementado de desenvolver doença de alzheimer e se um paciente é responsivo a tratamento para uma condição de interesse
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
MX339844B (es) 2011-01-10 2016-06-13 Takeda Pharmaceuticals Co Metodos y productos de farmaco para tratar enfermedad de alzheimer.
US8703763B2 (en) * 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
US9675796B2 (en) 2013-11-10 2017-06-13 Brainsgate Ltd. Implant and delivery system for neural stimulator
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
WO2016100940A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator
EP3538516B1 (en) * 2016-11-08 2021-06-16 F. Hoffmann-La Roche AG Phenoxytriazoles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives

Also Published As

Publication number Publication date
KR20040007216A (ko) 2004-01-24
CN1443166A (zh) 2003-09-17
CA2407345C (en) 2009-04-07
DE60116080D1 (de) 2006-01-26
ZA200208134B (en) 2004-01-22
WO2001081309A2 (en) 2001-11-01
AU6021301A (en) 2001-11-07
MXPA02010573A (es) 2003-03-10
ATE313527T1 (de) 2006-01-15
PE20011229A1 (es) 2001-12-08
JP2004509837A (ja) 2004-04-02
ES2254422T3 (es) 2006-06-16
DK1278730T3 (da) 2006-05-01
BR0110233A (pt) 2003-01-21
EP1278730B1 (en) 2005-12-21
CA2407345A1 (en) 2001-11-01
JP3831255B2 (ja) 2006-10-11
UY26681A1 (es) 2001-10-25
AU785153B2 (en) 2006-10-05
US6432985B2 (en) 2002-08-13
CN1178914C (zh) 2004-12-08
WO2001081309A3 (en) 2002-01-17
US20010047014A1 (en) 2001-11-29
KR100527527B1 (ko) 2005-11-09
DE60116080T2 (de) 2006-08-24
EP1278730A2 (en) 2003-01-29

Similar Documents

Publication Publication Date Title
ID29609A (id) Turunan 2-(purin-9-il)-tetrahidrofuran-3,4-diol
ID28219A (id) Turunan 2-(purin-9-il) -tetrahidrofuran-3,4-diol
MX242679B (es) Antranilamidas insecticidas.
DK1226127T3 (da) Substituerede phenylsulfamoylcarboxamider
ATE307121T1 (de) Substituierte arylpyrazine
FI20000004A0 (fi) Flavonoidilääke...
AR028393A1 (es) Iminoazidas substituidas
AR028357A1 (es) 4-bencil-1-[2-(4-hidroxi-fenoxi)-etil]-piperidin-3,4-diol
DE50112662D1 (de) Substituierte benzoylcyclohexenone
AR028302A1 (es) Feniluracilos substituidos
CH695519A5 (de) Sperrstromthyristor.
AR027974A1 (es) 1-aril-ciclopropilmetilamino-1,3,5-triazinas substituidas
ES1046567Y (es) Tromel deshidratador perfeccionado.
ES1046656Y (es) Microplanta de transferencia de residuos solidos urbanos.
ES1047994Y (es) Tirachinas perfeccionado.
ES1047010Y (es) Portalamparas.
ES1045851Y (es) Cubitera.
ES1047836Y (es) Hidrobicicleta.
IT249307Y1 (it) Ciabatta.
IT1316979B1 (it) Grigliatrice.
ES1049032Y (es) Bitubo.
ES1047305Y (es) Embudo anti-rebosamiento.
ES1047650Y (es) Sacacorchos mejorado.
ES1045935Y (es) Pupitre-silla mejorado.
ES1046417Y (es) Maquina recrativa.

Legal Events

Date Code Title Description
FG Grant, registration